Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus monotherapy in idiopathic membranous nephropathy
NCT03549663Unknown
- Sponsor
- Xinhua Hospital
- Start
- Jul 2018
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of tacrolimus + Wuzhi capsule in idiopathic membranous nephropathy (IMN), sponsored by Xinhua Hospital. Primary endpoint: Complete Remission Rate at 48 weeks. Status: unknown.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT03549663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549663.